Literature DB >> 29139564

Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease.

Nicholas T Vozoris1,2,3, Xuesong Wang4, Peter C Austin4,5, Denis E O'Donnell6, Shawn D Aaron7, Teresa M To4,5, Andrea S Gershon3,4,5,8.   

Abstract

AIMS: Diuretic drugs may theoretically improve respiratory health outcomes in chronic obstructive pulmonary disease (COPD) through several possible mechanisms, but they might also lead to respiratory harm. We evaluated the association of incident oral diuretic drug use with respiratory-related morbidity and mortality among older adults with COPD.
METHODS: This was a population-based, retrospective cohort study using health administrative data from Ontario, Canada, for the period 2008-2013. We identified adults aged 66 years and older with nonpalliative COPD using a validated algorithm. Respiratory-related morbidity and mortality were evaluated within 30 days of incident oral diuretic drug use compared to nonuse using Cox proportional hazard regression and applying inverse probability of treatment weighting using the propensity score to minimize confounding.
RESULTS: Out of 99 766 individuals aged 66 years and older with COPD identified, incident diuretic receipt occurred in 51.7%. Relative to controls, incident diuretic users had significantly increased rates for hospitalization for COPD or pneumonia [hazard ratio (HR) 1.22, 95% confidence interval (CI) 1.07-1.40], as well as more emergency room visits for COPD or pneumonia (HR 1.35, 95% CI 1.18-1.56), COPD or pneumonia-related mortality (HR 1.41; 95% CI 1.04-1.92) and all-cause mortality (HR 1.20, 95% CI 1.06-1.35). The increased respiratory-related morbidity and mortality observed were specifically as a result of loop diuretic use.
CONCLUSIONS: Incident diuretic drugs, and more specifically loop diuretics, were associated with increased rates of respiratory-related morbidity and mortality among older adults with nonpalliative COPD. Further studies are needed to determine if this association is causative or due to unresolved confounding.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  chronic obstructive pulmonary disease; diuretics; health administrative database research; health outcomes research; pharmacoepidemiology

Mesh:

Substances:

Year:  2017        PMID: 29139564      PMCID: PMC5809361          DOI: 10.1111/bcp.13465

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  34 in total

1.  Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.

Authors:  Adrian R Levy; Bernie J O'Brien; Connie Sellors; Paul Grootendorst; Donald Willison
Journal:  Can J Clin Pharmacol       Date:  2003

2.  The adjunctive effect of nebulized furosemide in COPD exacerbation: a randomized controlled clinical trial.

Authors:  Hojat Sheikh Motahar Vahedi; Babak Mahshidfar; Helaleh Rabiee; Soheil Saadat; Hamid Shokoohi; Mojtaba Chardoli; Vafa Rahimi-Movaghar
Journal:  Respir Care       Date:  2013-04-30       Impact factor: 2.258

3.  Incident opioid drug use and adverse respiratory outcomes among older adults with COPD.

Authors:  Nicholas T Vozoris; Xuesong Wang; Hadas D Fischer; Chaim M Bell; Denis E O'Donnell; Peter C Austin; Anne L Stephenson; Sudeep S Gill; Paula A Rochon
Journal:  Eur Respir J       Date:  2016-07-13       Impact factor: 16.671

4.  The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life.

Authors:  Helena Elkington; Patrick White; Julia Addington-Hall; Roger Higgs; Polly Edmonds
Journal:  Palliat Med       Date:  2005-09       Impact factor: 4.762

5.  The analysis of rates using Poisson regression models.

Authors:  E L Frome
Journal:  Biometrics       Date:  1983-09       Impact factor: 2.571

6.  Susceptibility to exacerbation in chronic obstructive pulmonary disease.

Authors:  John R Hurst; Jørgen Vestbo; Antonio Anzueto; Nicholas Locantore; Hana Müllerova; Ruth Tal-Singer; Bruce Miller; David A Lomas; Alvar Agusti; William Macnee; Peter Calverley; Stephen Rennard; Emiel F M Wouters; Jadwiga A Wedzicha
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

7.  Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease.

Authors:  Kian-Chung Ong; Ai-Ching Kor; Wai-Fung Chong; Arul Earnest; Yee-Tang Wang
Journal:  Am J Respir Crit Care Med       Date:  2004-02-20       Impact factor: 21.405

8.  Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD.

Authors:  Nicholas T Vozoris; Hadas D Fischer; Xuesong Wang; Anne L Stephenson; Andrea S Gershon; Andrea Gruneir; Peter C Austin; Geoffrey M Anderson; Chaim M Bell; Sudeep S Gill; Paula A Rochon
Journal:  Eur Respir J       Date:  2014-04-17       Impact factor: 16.671

9.  Effect of low-dose acetazolamide on the ventilatory CO2 response during hypoxia in the anaesthetized cat.

Authors:  M Wagenaar; L Teppema; A Berkenbosch; C Olievier; H Folgering
Journal:  Eur Respir J       Date:  1998-12       Impact factor: 16.671

10.  Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD.

Authors:  D Jensen; K Amjadi; V Harris-McAllister; K A Webb; D E O'Donnell
Journal:  Thorax       Date:  2008-02-04       Impact factor: 9.139

View more
  4 in total

1.  Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease.

Authors:  Nicholas T Vozoris; Xuesong Wang; Peter C Austin; Denis E O'Donnell; Shawn D Aaron; Teresa M To; Andrea S Gershon
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

2.  Predictors of acute cardiovascular events following acute exacerbation period for patients with COPD: a nested case-control study.

Authors:  Wei-Ping Hu; Tsokyi Lhamo; Feng-Ying Zhang; Jing-Qing Hang; Yi-Hui Zuo; Jian-Lan Hua; Shan-Qun Li; Jing Zhang
Journal:  BMC Cardiovasc Disord       Date:  2020-12-10       Impact factor: 2.298

3.  Risk Estimation for Infection in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Development and Validation of a Predictive Score.

Authors:  Yuanhui Liu; Litao Wang; Pengyuan Chen; Yining Dai; Yaowang Lin; Wei Chen; Zhengrong Xu; Lihuan Zeng; Hualin Fan; Ling Xue; Simin Liu; Jiyan Chen; Ning Tan; Pengcheng He; Chongyang Duan
Journal:  Front Cardiovasc Med       Date:  2022-04-15

4.  Quality of reporting of drug exposure in pharmacoepidemiological studies.

Authors:  Mirjam Hempenius; Kim Luijken; Anthonius de Boer; Olaf Klungel; Rolf Groenwold; Helga Gardarsdottir
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-05-11       Impact factor: 2.890

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.